Intensity Therapeutics (INTS) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 13, 2023
Document Information Line Items
Entity Registrant Name	Intensity Therapeutics, Inc.
Trading Symbol	INTS
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		13,709,377
Amendment Flag	false
Entity Central Index Key	0001567264
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-41109
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-1488089
Entity Address, Address Line One	1 Enterprise Drive
Entity Address, Address Line Two	Suite 430
Entity Address, City or Town	Shelton
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06484-4779
City Area Code	(203)
Local Phone Number	221-7381
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,693,825	$ 1,311,877
Marketable debt securities	8,955,316
Prepaid expenses	971,239	62,924
Other current assets	14,366	75,535
Total current assets	16,634,746	1,450,336
Right-of-use asset, net	152,605	139,089
Other assets	28,438	167,738
Total assets	16,815,789	1,757,163
Current liabilities:
Accounts payable	358,404	603,176
Accrued expenses	355,006	1,723,400
Current lease liability	10,556	143,221
Convertible note and accrued interest		4,348,548
Total current liabilities	723,966	6,818,345
Long-term lease liability	144,891
Total liabilities	904,857	6,854,345
Series A redeemable convertible preferred stock, par value $.0001. Authorized, issued, and outstanding shares of none and 5,000,000 as of September 30, 2023 and December 31, 2022, respectively.		10,000,000
STOCKHOLDERS’ EQUITY (DEFICIENCY)
Preferred stock
Common stock, par value $.0001. Authorized shares of 135,000,000 and 50,000,000 as of September 30, 2023 and December 31, 2022, respectively. Issued and outstanding shares of 13,709,377 and 3,410,103 as of September 30, 2023 and December 31, 2022, respectively.	1,371	341
Additional paid-in capital	63,252,862	23,555,160
Accumulated deficit	(47,343,301)	(38,653,008)
Total stockholders’ equity (deficiency)	15,910,932	(15,097,182)
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficiency)	16,815,789	1,757,163
Series B Convertible Preferred Stock
STOCKHOLDERS’ EQUITY (DEFICIENCY)
Preferred stock		145
Series C Convertible Preferred Stock
STOCKHOLDERS’ EQUITY (DEFICIENCY)
Preferred stock		180
Related Party
Current liabilities:
Related party deposit	$ 36,000	$ 36,000

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock,shares authorized		15,000,000
Preferred stock,shares issued		15,000,000
Preferred stock,shares outstanding		15,000,000
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock shares authorized	135,000,000	50,000,000
Common stock shares issued	13,709,377	3,410,103
Common stock shares outstanding	13,709,377	3,410,103
Series A Redeemable Convertible Preferred Stock
Temporary equity par value per share (in Dollars per share)	$ 0.0001	$ 0.0001
Temporary equity shares authorized		5,000,000
Temporary equity shares issued		5,000,000
Temporary equity shares outstanding		5,000,000
Series B Convertible Preferred Stock
Preferred stock,shares authorized		1,449,113
Preferred stock,shares issued		1,449,113
Preferred stock,shares outstanding		1,449,113
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Series C Convertible Preferred Stock
Preferred stock,shares authorized		1,800,606
Preferred stock,shares issued		1,800,606
Preferred stock,shares outstanding		1,800,606
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development costs	$ 1,351,766	$ 1,160,737	$ 2,984,752	$ 4,241,203
General and administrative costs	1,138,748	607,113	1,981,594	1,834,966
Total operating expenses	2,490,514	1,767,850	4,966,346	6,076,169
Loss from operations	(2,490,514)	(1,767,850)	(4,966,346)	(6,076,169)
Other income (expense):
Interest income	147,539	988	148,026	1,844
Interest expense		(15,123)	(305,161)	(44,877)
Loss on debt extinguishment			(2,261,581)
Other	13,230	7,118	18,304	47,646
Net loss	(2,329,745)	(1,774,867)	(7,366,758)	(6,071,556)
Preferred stock deemed dividend			(1,323,535)
Net loss attributable to common stockholders	$ (2,329,745)	$ (1,774,867)	$ (8,690,293)	$ (6,071,556)
Loss per share, basic (in Dollars per share)	$ (0.17)	$ (0.52)	$ (1.26)	$ (1.78)
Weighted average number of shares of common stock, basic (in Shares)	13,660,627	3,410,103	6,899,984	3,410,103

Condensed Statements of Opera_2

Condensed Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Loss per share, diluted	$ (0.17)	$ (0.52)	$ (1.26)	$ (1.78)
Weighted average number of shares of common stock, diluted	13,660,627	3,410,103	6,899,984	3,410,103

Condensed Statements of Changes

Condensed Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficiency) (Unaudited) - USD ($)	Series A Redeemable Convertible Preferred Stock	Series B Convertible Preferred Stock	Series C Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
Balances at Dec. 31, 2021	$ 10,000,000	$ 145	$ 180	$ 341	$ 22,386,341	$ (31,071,111)	$ (8,684,104)
Balances (in Shares) at Dec. 31, 2021	5,000,000	1,449,113	1,800,606	3,410,103
Stock-based compensation expense					541,333		541,333
Net loss						(6,071,556)	(6,071,556)
Balances at Sep. 30, 2022	$ 10,000,000	$ 145	$ 180	$ 341	22,927,674	(37,142,667)	(14,214,327)
Balances (in Shares) at Sep. 30, 2022	5,000,000	1,449,113	1,800,606	3,410,103
Balances at Jun. 30, 2022	$ 10,000,000	$ 145	$ 180	$ 341	22,886,963	(35,367,800)	(12,480,171)
Balances (in Shares) at Jun. 30, 2022	5,000,000	1,449,113	1,800,606	3,410,103
Stock-based compensation expense					40,711		40,711
Net loss						(1,774,867)	(1,774,867)
Balances at Sep. 30, 2022	$ 10,000,000	$ 145	$ 180	$ 341	22,927,674	(37,142,667)	(14,214,327)
Balances (in Shares) at Sep. 30, 2022	5,000,000	1,449,113	1,800,606	3,410,103
Balances at Dec. 31, 2022	$ 10,000,000	$ 145	$ 180	$ 341	23,555,160	(38,653,008)	(15,097,182)
Balances (in Shares) at Dec. 31, 2022	5,000,000	1,449,113	1,800,606	3,410,103
Stock-based compensation expense					975,422		975,422
Warrants issued to convertible note holders					159,262		159,262
Warrants issued to underwriters in connection with public offering and overallotment					1,169,719		1,169,719
Issuance of common stock in public offering for cash, net of $3,031,484 issuance costs				$ 390	16,468,126		16,468,516
Issuance of common stock in public offering for cash, net of $3,031,484 issuance costs (in Shares)				3,900,000
Issuance of common stock in overallotment for cash, net of issuance costs				$ 59	2,553,358		2,553,417
Issuance of common stock in overallotment for cash, net of issuance costs (in Shares)				585,000
Conversion of preferred stock into common stock	$ (10,000,000)	$ (145)	$ (180)	$ 413	9,999,868		9,999,956
Conversion of preferred stock into common stock (in Shares)	(5,000,000)	(1,449,113)	(1,800,606)	4,124,851
Conversion of convertible notes into common stock				$ 140	6,998,440		6,998,580
Conversion of convertible notes into common stock (in Shares)				1,399,716
Exercise of options and warrants				$ 2	49,998		50,000
Exercise of options and warrants (in Shares)				25,000
Deemed dividend				$ 26	1,323,509	(1,323,535)
Deemed dividend (in Shares)				264,707
Net loss						(7,366,758)	(7,366,758)
Balances at Sep. 30, 2023		$ 0	$ 0	$ 1,371	63,252,862	(47,343,301)	15,910,932
Balances (in Shares) at Sep. 30, 2023				13,709,377
Balances at Jun. 30, 2023				$ 1,310	60,145,764	(45,013,556)	15,133,518
Balances (in Shares) at Jun. 30, 2023				13,099,377
Stock-based compensation expense					351,169		351,169
Warrants issued to underwriters in connection with public offering and overallotment					152,573		152,573
Issuance of common stock in overallotment for cash, net of issuance costs				$ 59	2,553,358		2,553,417
Issuance of common stock in overallotment for cash, net of issuance costs (in Shares)				585,000
Exercise of options and warrants				$ 2	49,998		50,000
Exercise of options and warrants (in Shares)				25,000
Net loss						(2,329,745)	(2,329,745)
Balances at Sep. 30, 2023		$ 0	$ 0	$ 1,371	$ 63,252,862	$ (47,343,301)	$ 15,910,932
Balances (in Shares) at Sep. 30, 2023				13,709,377

Condensed Statements of Chang_2

Condensed Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficiency) (Unaudited) (Parentheticals) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]
Stock issuance costs		$ 3,031,484
Overallotment of net issuance costs	$ 371,583	$ 371,583

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (7,366,758)	$ (6,071,556)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on convertible notes	159,262
Change in carrying value of right-of-use asset	141,108	133,605
Stock-based compensation expense	975,422	541,333
Loss on debt extinguishment	2,261,581
Changes in operating assets and liabilities, net:
Accrued interest on marketable debt securities	(110,937)
Prepaid expenses	(908,315)	32,384
Other current assets	61,169	2,353
Other assets	139,300
Accounts payable	(244,772)	623,797
Accrued expenses	(1,368,394)	986,189
Accrued interest on convertible note	145,899	44,877
Change in lease liabilities	(142,398)	(135,645)
Net cash used in operating activities	(6,257,833)	(3,842,663)
Cash flows from investing activities:
Purchase of marketable debt securities	(8,844,379)
Net cash used in investing activities	(8,844,379)
Cash flows from financing activities:
Proceeds from issuance of convertible note	242,552
Payout of fractional shares on reverse split	(44)
Proceeds from Initial Public Offering	19,500,000
Proceeds from overallotment shares	2,925,000
Issuance costs related to initial public offering and overallotment	(2,233,348)
Proceeds from exercise of options and warrants	50,000
Net cash provided by financing activities	20,484,160
Net increase (decrease) in cash and cash equivalents	5,381,948	(3,842,663)
Cash and cash equivalents at beginning of period	1,311,877	4,539,229
Cash and cash equivalents at end of period	6,693,825	696,566
Supplemental disclosure of non-cash financing activities:
Right-of-use lease asset and operating lease liability	154,624
Conversion of convertible notes and accrued interest into common stock	4,736,999
Warrants issued in relation to issuance of convertible notes	159,262
Warrants issued to underwriter in connection with stock issuance	1,169,719
Preferred stock deemed dividend	$ 1,323,535

Nature of Business

Nature of Business	9 Months Ended
	Sep. 30, 2023
Nature of Business [Abstract]
Nature of Business	Note A — Nature of Business Intensity Therapeutics, Inc. (“the Company”) is Connecticut-based and incorporated in Delaware in December 2012. The Company is a biotechnology company whose treatment approach addresses both the regional and systemic nature of a patient’s cancer. The Company’s DfuseRx SM As a result of its initial public offering (“IPO”) that priced on June 29, 2023, the Company began trading on the Nasdaq Capital Market under the symbol “INTS” on June 30, 2023. The IPO closed on July 5, 2023, at which time the Company issued 3,900,000 shares of our common stock and received gross proceeds of $19,500,000 less some of the issuance costs for a cash transfer of $17,765,000. There were additional issuance costs on the IPO of approximately $264,000. The IPO shares were issued on July 5, 2023, the closing date, at the time that the net proceeds were transferred to the Company. On July 7, 2023, the Company sold the full overallotment shares of the IPO. The overallotment resulted in the issuance of 585,000 shares of our common stock, and the Company received $2,691,000 in net cash proceeds. The Company has begun to use and will continue to use the net proceeds from the IPO and overallotment to complete pre-clinical and clinical studies, conduct manufacturing suitable for phase 3 studies, submit regulatory filings to the United States Food & Drug Administration (“FDA”) and for general and corporate purposes. On April 27, 2023, the Company effected a two-for-one reverse stock split (the “Reverse Stock Split”). All owners of record as of April 27, 2023 received one issued and outstanding share of the Company’s common stock in exchange for two outstanding shares of the Company’s common stock. All fractional shares created by the two-for-one exchange were paid in cash. The conversion price of Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock were adjusted to reflect the Reverse Stock Split by doubling the original conversion price. The Reverse Stock Split has no impact on the par value per share of the Company’s common stock, Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock, all of which remain at $.0001. All holders of options and warrants had the exercise price doubled and the number of shares issuable upon exercise reduced by half. All current and prior period amounts related to shares, share prices and loss per share, presented in the Company’s financial statements and the accompanying notes have been restated for the Reverse Stock Split. All preferred stock and convertible notes that were issued during the pre-IPO period were converted into common stock.

Liquidity and Plan of Operation

Liquidity and Plan of Operation	9 Months Ended
	Sep. 30, 2023
Liquidity and Plan of Operation [Abstract]
Liquidity and Plan of Operation	Note B — Liquidity and Plan of Operation The accompanying unaudited condensed financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern. The Company is a research and development company and has not generated any revenue from its product candidates. The Company, therefore, has experienced net losses and negative cash flows from operations each year since its inception. Through September 30, 2023, the Company has an accumulated deficit of approximately $47.3 million. The Company’s operations have been financed primarily through the sale of equity securities and convertible notes. The Company’s net loss for the nine months ended September 30, 2023 was approximately $7.4 million. To date, the Company has not obtained regulatory approval for any of its product candidates. The Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability. The Company does not expect to receive significant product revenue in the near term. The Company, therefore, expects to continue to incur substantial losses for the foreseeable future. Cash and cash equivalents at September 30, 2023 totaled approximately $6.7 million. The Company’s investment in marketable debt securities totaled approximately $9.0 million at September 30, 2023. These two accounts total approximately $15.7 million. Until such time, if ever, as the Company can generate substantial product revenue, the Company expects to finance its operational needs through a combination of equity offerings and convertible debt financings. The Company does not have any committed external source of funds. To the extent that the Company can raise additional capital through the sale of equity or convertible debt securities, the ownership interest of the Company stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the common stockholders. If the Company is unable to raise additional funds through equity or debt financings when needed, the Company may be required to delay, limit, reduce or terminate its research and product development. Based on the cash, cash equivalents, and investment in marketable debt securities as of September 30, 2023, the Company expects its cash and cash equivalents to be sufficient to fund operations for a period of at least 12 months from the date that these financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Accounts	9 Months Ended
	Sep. 30, 2023
Summary of Significant Accounting Policies and Accounts [Abstact]
Summary of Significant Accounting Policies and Accounts	Note C — Summary of Significant Accounting Policies and Accounts [1] Basis of presentation: The accompanying condensed financial statements include the accounts of Intensity Therapeutics, Inc. These condensed financial statements have been prepared in accordance with the instructions to Form 10-Q and therefore do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the United States of America (“GAAP”); however, such information reflects all adjustments consisting solely of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods. The condensed financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s prospectus, dated June 29, 2023 and filed with the Securities and Exchange Commission on June 30, 2023. [2] Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Certain accounting principles require subjective and complex judgments to be used in the preparation of financial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used. The Company utilizes significant estimates and assumptions in valuing its stock-based awards. An additional significant estimate is that these financial statements are based on the assumption of the Company continuing as a going concern. See Note B with regard to the Company’s ability to continue as a going concern. [3] Concentration of credit risk: The Company’s financial instruments that are exposed to concentrations of credit risk consist entirely of cash and investments in U.S. Treasury bills. These financial instruments are held at two U.S. financial institutions. The cash accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. During the nine months ended September 30, 2023 and 2022, the Company’s cash balances exceeded the FDIC insurance limit. The investments in U.S. Treasury bills are not FDIC insured but are backed by the U.S. government. U.S. Treasury bills are subject to market risk if they are sold prior to maturity. The Company has not experienced any losses in such accounts. Although the Company believes that the financial institutions with whom the Company does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so beyond amounts guaranteed by the FDIC. [4] Cash and cash equivalents: The Company considers all liquid investments with an original maturity of three months or less to be cash equivalents. [5] Marketable debt securities: Investments in U.S. Treasury bills purchased with an original maturity over three months are classified separately from cash and cash equivalents in current assets. Investments in U.S. Treasury bills are classified as available for sale. Under the classification of available for sale, securities are reported at fair value. Unrealized gains or losses would be included in accumulated other comprehensive income within the equity section of the Balance Sheet. At September 30, 2023, there were no unrealized gains or losses and all accrued interest was recognized as Interest income in the Statement of Operations. [6] Fair value measurement: The Company reports its investments at fair value. Fair value is an estimate of the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (i.e., the exit price at the measurement date). Fair value measurements are not adjusted for transaction costs. A fair value hierarchy provides for prioritizing inputs to valuation techniques used to measure fair value into three levels: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company. Level 3 Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability. An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 or Level 2 assets or liabilities. At September 30, 2023, the Company has a total of approximately $9.0 million invested in U.S. Treasury Bills: none is included in cash and cash equivalents and $9.0 million is included in marketable debt securities. U.S. Treasury bills are valued at market price. U.S. Treasury Bills are categorized in Level 1 of their fair value hierarchy. At December 31, 2022, there were no investments in U.S. Treasury Bills. The Company’s financial instruments, including cash equivalents and current liabilities are carried at cost, which approximates fair value due to the short-term nature of these instruments. [7] Stock-based compensation: The Company accounts for stock-based compensation to employees and non-employees, which consists of stock option grants, through the Statements of Operations based on their fair values at the date of grant. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. Forfeitures are recognized as they occur. [8] Research and development and patent costs: Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred, due to the uncertainty with respect to future cash flows resulting from the patents and are included as part of general and administrative expenses in the Company’s Statements of Operations. [9] Income taxes: The Company accounts for income taxes through the use of the asset-and-liability method whereby deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company utilizes a valuation allowance to reduce deferred tax assets to their estimated realizable value. The Company accounts for uncertain tax positions. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At September 30, 2023, the Company does not have any significant uncertain tax positions. There are no estimated interest costs and penalties provided for in the Company’s financial statements for the nine months ended September 30, 2023. If at any time the Company should record interest and penalties in connection with income taxes, the interest and penalties will be expensed within the income tax line. The Company’s income tax returns are subject to Federal, state and local income tax examination by the authorities for the last three tax years. [10] Leases: The Company determines if an arrangement contains a lease at contract inception. With the exception of short-term leases (leases with terms less than 12 months), all leases with contractual fixed costs are recorded on the balance sheet on the commencement date as a right-of-use (ROU) asset and a lease liability. Lease liabilities to be paid over the next twelve months are classified as current lease liability and all other lease obligations are classified as long-term lease liability. Lease liabilities are initially measured at the present value of the future minimum lease payments and subsequently increased to reflect the interest accrued and reduced by the lease payments made. The Company’s building leases require a pro-rata share of operating expenses and real estate taxes, which are variable in nature and excluded from the measurement of lease liabilities. ROU assets are initially measured at the present value of the future minimum lease payments adjusted for any prior lease pre-payments, lease incentives and initial direct costs. Certain leases contain escalation, renewal and/or termination options that are factored into the ROU asset as appropriate. Operating leases result in a straight-line rent expense over the expected lease term. The Company uses its estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of future lease payments, if the rate implicit in the lease is not readily determinable. Consideration is given to publicly available data for instruments with similar characteristics when calculating incremental borrowing rates. This incremental borrowing rate estimate is based on a synthetic credit rating derived from the market capitalization of similar companies, the treasury yield curve, and corporate yield spreads. [11] Basic and dilutive loss per share: Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Dilutive net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options, and stock warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per share does not include the conversion of securities that would have an anti-dilutive effect. Potential shares of common stock issuable upon conversion of preferred stock, exercise of stock options, and exercise of warrants that are excluded from the computation of diluted weighted average shares outstanding listed in the table below because they are anti-dilutive. The basic and diluted computation of net loss per share for the Company are the same because the effects of the Company’s convertible securities would be anti-dilutive. All common and preferred stock participate equally in dividends and the distribution of earnings if and when declared by the Board of Directors, on the Company’s common stock for the three and nine months ended September 30, 2022. For purposes of computing earnings per share, all series of preferred stock are considered participating securities. Therefore, the Company must calculate basic and diluted earnings per share using the two-class method. Under the two-class method, net income for the period is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed earnings. As the preferred stockholders have no obligation to fund losses no portion of net loss was allocated to the participating securities for the three months or nine months ended September 30, 2022. There were no preferred shares outstanding at September 30, 2023. At September 30, 2023 and 2022, the following shares of common stock underlying preferred stock, options, and warrants were excluded from the computation of diluted weighted average shares outstanding. In accordance with the Reverse Stock Split on April 27, 2023 (see Note A), the number of shares of common stock underlying the preferred stock, options and warrants are now half, and the below information gives effect to this Reverse Stock Split: September 30, September 30, 2023 2022 Preferred stock Series A outstanding - 2,499,999 Preferred stock Series B outstanding - 724,552 Preferred stock Series C outstanding - 900,300 Options outstanding 1,081,750 851,250 Warrants outstanding 689,200 323,250 1,770,950 5,299,351 As of September 30, 2022 the shares that would be issued from the convertible notes outstanding are also excluded from diluted weighted average shares outstanding, since the conversion rate is dependent upon qualified liquidity events. All convertible notes were converted into shares of common stock on June 29, 2023. [12] Stock issuance costs: The Company incurred costs related to the sale of its common stock in its IPO and the subsequent sale of common stock in the overallotment. These costs included underwriter commissions and fees, legal fees, accounting fees, and printing costs. These costs were recorded as a deduction to Additional Paid in Capital. [13] Recently issued pronouncements: The Company does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material impact on its financial statements. [14] Reclassifications: Certain prior year amounts have been reclassified to conform to current year presentation.

Marketable Debt Securities

Marketable Debt Securities	9 Months Ended
	Sep. 30, 2023
Marketable Debt Securities [Abstract]
Marketable Debt Securities	Note D — Marketable Debt Securities Marketable debt securities consist of U.S. Treasury bills purchased with original maturities of at least three months, but less than twelve months. Securities with a maturity value of $9,030,000 were purchased for $8,844,400. At September 30, 2023, these securities were recorded at a market value of $8,955,300.

Prepaid Expenses

Prepaid Expenses	9 Months Ended
	Sep. 30, 2023
Prepaid Expenses [Abstract]
Prepaid Expenses	Note E — Prepaid Expenses Prepaid expenses at September 30, 2023 and December 31, 2022 include: September 30, December 31, Prepaid insurance $ 917,807 $ 29,359 Prepaid rent - 16,200 Prepaid other 53,432 17,365 $ 971,239 $ 62,924

Other Current Assets

Other Current Assets	9 Months Ended
	Sep. 30, 2023
Other Current Assets [Abstract]
Other Current Assets	Note F — Other Current Assets Other current assets at September 30, 2023 and December 31, 2022 include: September 30, December 31, Tax credit receivable $ 8,785 $ 15,903 Receivable with related party - 46,401 State income tax receivable 5,581 13,231 $ 14,366 $ 75,535

Other Assets

Other Assets	9 Months Ended
	Sep. 30, 2023
Other Assets [Abstract]
Other Assets	Note G — Other Assets Other assets at September 30, 2023 and December 31, 2022 include: September 30, December 31, Deposit with vendor $ - $ 150,000 Deposits with landlords 28,438 17,738 $ 28,438 $ 167,738

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2023
Accrued Expenses [Abstract]
Accrued Expenses	Note H — Accrued Expenses Accrued expenses at September 30, 2023 and December 31, 2022 include: September 30, December 31, Accrued vacation, wages, and related payroll taxes $ - $ 328,527 Patient costs incurred but not yet invoiced 340,639 1,392,604 Accrued other 14,367 2,269 $ 355,006 $ 1,723,400

Convertible Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2023
Convertible Notes [Abstract]
Convertible Notes	Note I — Convertible Notes Prior to the June 29, 2023 IPO, the Company entered into a series of interest bearing convertible notes described below. On June 29, 2023, all notes converted to shares following the pricing of the IPO. On September 20, 2021, the Company entered into a convertible debt agreement (the “2021 Convertible Note”) with a shareholder for aggregate principal of $2,000,000 due October 1, 2025, as amended on November 29, 2022, with the following conversion terms. The outstanding principal balance together with the unpaid and accrued interest of the note would be automatically converted upon the earlier of (i) an IPO in excess of $7,000,000 gross proceeds, (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non-IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of October 1, 2025. If an IPO, sale event or Non-IPO financing occurred between September 20, 2021 through September 19, 2022 a conversion price discount of 25% would be assessed, if between September 20, 2022 through March 19, 2023 a conversion price discount of 30% would be assessed, if between March 20, 2023 through October 1, 2025 a conversion price discount of 35% would be assessed. Otherwise at the maturity date a conversion price of $11.50 per share would be assessed. The 2021 Convertible Note accrues interest at 3% per annum, convertible to shares as previously described herein. On November 29, 2022 this agreement was amended so that the interest rate changes to 6% per annum after October 1, 2023. The occurrence of any of the following would constitute an event of default: a) failure to pay when due any principal payment; b) voluntary bankruptcy or insolvency proceedings; c) involuntary bankruptcy or insolvency proceedings; d) judgements in excess of $500,000; or e) defaults under other indebtedness. Under these occurrences, the holder may declare all outstanding principal and interest payable to be immediately due and payable. On November 21, 2022, the Company entered into two convertible debt agreements (the “November 21, 2022 Convertible Notes”) with shareholders for $250,000 and $500,000. The outstanding principal balance together with the unpaid and accrued interest of the note would be automatically converted upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds, as amended (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non-IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of November 21, 2024. If an IPO, sale event or Non-IPO financing occurred prior to November 21, 2024 a conversion price discount of 30% would be assessed. Otherwise at the maturity date a conversion price of $11.50 per share would be assessed. The November 21, 2022 Convertible Notes accrue interest at 10% per annum, convertible to shares as previously described herein. The occurrence of any of the following would constitute an event of default: a) failure to pay when due any principal payment; b) voluntary bankruptcy or insolvency proceedings; c) involuntary bankruptcy or insolvency proceedings; d) judgements in excess of $500,000; or e) defaults under other indebtedness. Under these occurrences, the holders may declare all outstanding principal and interest payable to be immediately due and payable. On November 29, 2022, the Company entered into a convertible debt agreement (the “November 29, 2022 Convertible Note”) for $1,500,000 with a holder. The outstanding principal balance together with the unpaid and accrued interest of the note would be automatically converted upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds, as amended (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of October 1, 2025. If an IPO, sale event or Non-IPO financing occurred prior to October 1, 2025 a conversion price discount of 30% would be assessed. Otherwise at the maturity date a conversion price of $11.50 per share would be assessed. The November 29, 2022 Convertible Note accrues interest at 10% per annum, convertible to shares as previously described herein. The occurrence of any of the following would constitute an event of default: a) failure to pay when due any principal payment; b) voluntary bankruptcy or insolvency proceedings; c) involuntary bankruptcy or insolvency proceedings; d) judgements in excess of $500,000; or e) defaults under other indebtedness. Under these occurrences, the holder may declare all outstanding principal and interest payable to be immediately due and payable. On March 16, 2023, the Company entered into a convertible debt agreement (the “March 16, 2023 Convertible Note”) for $50,000 with a holder. On March 30, 2023 the Company entered into a convertible note debt agreement (the “March 30, 2023 Convertible Note”) for $155,000 with a holder. The outstanding principal balances together with the unpaid and accrued interest of these notes would be automatically converted upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of March 16, 2026 for the March 16, 2023 Convertible Note and March 30, 2026 for the March 30, 2023 Convertible Note. If an IPO, sale event or Non-IPO financing occurred prior to March 16, 2026 for the March 16, 2023 Convertible Note or prior to March 30, 2026 for the March 30, 2023 Convertible Note, a conversion price discount of 30% would be assessed. Otherwise at the maturity date a conversion price of $11.50 per share would be assessed. These notes accrue interest at 10% per annum, convertible to shares as previously described herein. The occurrence of any of the following would constitute an event of default: a) failure to pay when due any principal payment; b) voluntary bankruptcy or insolvency proceedings; c) involuntary bankruptcy or insolvency proceedings; d) judgements in excess of $500,000; or e) defaults under other indebtedness. Under these occurrences, the holder may declare all outstanding principal and interest payable to be immediately due and payable. On April 1, 2023, the Company entered into a convertible debt agreement (the “April 1, 2023 Convertible Note”) for $12,552 with our landlord in exchange for services. The outstanding principal balances together with the unpaid and accrued interest of these notes would be automatically converted upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of April 1, 2026. If an IPO, sale event or Non-IPO financing occurred prior to April 1, 2026, a conversion price discount of 30% would be assessed. Otherwise at the maturity date a conversion price of $11.50 per share would be assessed. This note accrues interest at 10% per annum, convertible to shares as previously described herein. The occurrence of any of the following would constitute an event of default: a) failure to pay when due any principal payment; b) voluntary bankruptcy or insolvency proceedings; c) involuntary bankruptcy or insolvency proceedings; d) judgements in excess of $500,000; or e) defaults under other indebtedness. Under these occurrences, the holder may declare all outstanding principal and interest payable to be immediately due and payable. On May 11, 2023, the Company entered into a convertible debt agreement (the “May 11, 2023 Convertible Note”) for $25,000 with a holder. The outstanding principal balances together with the unpaid and accrued interest of these notes would be automatically converted upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of May 11, 2026. If an IPO, sale event or Non-IPO financing occurred prior to May 11, 2026, a conversion price discount of 30% would be assessed. Otherwise at the maturity date a conversion price of $11.50 per share would be assessed. These note accrues interest at 10% per annum, convertible to shares as previously described herein. The occurrence of any of the following would constitute an event of default: a) failure to pay when due any principal payment; b) voluntary bankruptcy or insolvency proceedings; c) involuntary bankruptcy or insolvency proceedings; d) judgements in excess of $500,000; or e) defaults under other indebtedness. Under these occurrences, the holder may declare all outstanding principal and interest payable to be immediately due and payable. A loss was recorded to account for the discount given to convertible noteholders as provided by their convertible note agreements. Upon the settlement of the notes, a loss of $2,261,581 was recorded on the Statement of Operations for the nine months ended September 30, 2023 for the discount given to the convertible debt holders. The balance at December 31, 2022 consists of: Principal Accrued Total Convertible note dated September 20, 2021 $ 2,000,000 $ 76,767 $ 2,076,767 Convertible notes dated November 21, 2022 750,000 8,219 758,219 Convertible note dated November 29, 2022 1,500,000 13,562 1,513,562 $ 4,250,000 $ 98,548 $ 4,348,548 There was no balance in Convertible notes as of September 30, 2023 since all principal and accrued interest of $4,492,552 and $244,447, respectively was converted into 1,399,716 shares of common stock on June 29, 2023. At December 31, 2022, the Company classified the convertible notes as a current liability since the Company anticipated that these notes will automatically convert into shares of common stock within one year of the balance sheet date. The unamortized discount was amortized over the life of the convertible notes. The unamortized balance at the time of the conversion into shares of common stock of approximately $117,700 is included in interest expense in the Statement of Operations.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2023
Stockholders’ Equity [Abstract]
Stockholders’ Equity	Note J — Stockholders’ Equity On June 29, 2023, as described in Note A, the Company priced its IPO, issuing 3,900,000 shares of common stock. Pursuant to the IPO, all of the Company’s preferred stock was converted into common stock at conversion prices that reflected the Reverse Stock Split effective June 29, 2023. All convertible notes and related accrued interest were converted into 1,399,716 shares of common stock, as described in Note I and the Company recorded a non-operating loss on debt extinguishment on the Statement of Operations for $2,261,581 which is equal to the discount on the IPO price that was specified in the convertible note agreements. As the IPO price was less than the original issue price per share of the Series B and Series C preferred stock, each of these series received a conversion price adjustment pursuant to their original terms. Upon conversion of the preferred stock, the Company issued an additional 100,189 shares of common stock pursuant to Series B conversion price adjustment and an additional 164,518 shares of common stock pursuant to the Series C conversion price adjustment. The additional shares have been recorded as a deemed dividend on the Statement of Operations and Statement of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficiency). On July 7, 2023, the Company sold the full overallotment of the IPO shares and issued 585,000 shares of common stock at the IPO price of $5.00 per share. The sixth amended and restated Certificate of Incorporation, which was approved by the Company’s stockholders on November 23, 2021, increased the number of authorized shares from 50,000,000 to 135,000,000 upon the completion of the IPO.

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Sep. 30, 2023
Common Stock Warrants [Abstract]
Common Stock Warrants	Note K — Common Stock Warrants The following table summarizes information about common stock warrants at September 30, 2023 and 2022: Number of Shares Weighted Outstanding January 1, 2022 323,250 $ 6.01 Issued - - Exercised - - Forfeited - - Outstanding March 31, 2022 323,250 6.01 Issued - Exercised - Forfeited - Outstanding June 30, 2022 323,250 6.01 Issued - Exercised - Forfeited - Outstanding September 30, 2022 323,250 $ 6.01 Outstanding January 1, 2023 357,750 $ 6.00 Issued 30,000 12.50 Exercised - Forfeited - Outstanding March 31, 2023 387,750 6.51 Issued 273,000 6.00 Exercised - Forfeited - Outstanding June 30, 2023 660,750 6.30 Issued 40,950 6.00 Exercised (12,500 ) 2.00 Forfeited - Outstanding September 30, 2023 689,200 $ 6.36 Exercisable September 30, 2023 659,450 $ 6.21 The following table summarizes the assumptions used to estimate the fair value of 30,000 stock warrants granted on January 1, 2023 at the date of grant: Stock price $ 4.50 Exercise price $ 6.25 Expected volatility 103.85 % Risk free interest rates 3.59 % Term 3 years 30,000 warrants were granted on January 1, 2023 to two holders of convertible notes. These warrants were exercisable upon issuance and expire in three years. The value of the warrants is $159,262. The value of the warrants is recorded as a discount to the convertible notes and was being amortized over the life of the convertible notes. The amortization appears on the Statement of Operations as interest expense. The following table summarizes the assumptions used to estimate the fair value of stock warrants committed by the Company on June 29 and July 7, 2023 as part of the IPO and sale of the IPO overallotment: Stock price $ 5.00 Exercise price $ 6.00 Expected volatility 101.46 % Risk free interest rates 3.97 % Term 5 years 273,000 warrants were granted to the underwriters of the IPO for the sale of the IPO base shares. The value of these warrants is approximately $1,017,000. 40,950 warrants were granted to the underwriters for the sale of the overallotment shares. The value of these warrants is approximately $153,000. All of these warrants are recorded as both an increase and decrease to Additional Paid in Capital on the Balance Sheet since they are costs related to the issuance of the shares of common stock. These warrants are exercisable beginning on January 5, 2024 and expire January 5, 2029. There was no stock compensation expense recorded on these warrants. The Company recognized stock-based compensation expense related to warrants in its condensed Statements of Operations as follows (approximately): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Research and Development $ 67,000 $ 4,000 $ 203,000 $ 11,000 General and Administrative 4,000 - 11,000 100,000 Total $ 71,000 $ 4,000 $ 214,000 $ 111,000 At September 30, 2023, total unrecognized compensation cost related to warrants was approximately $164,000 and is expected to be recognized over the remaining weighted average service period of 1.9 years. The aggregate intrinsic value of outstanding warrants is calculated as the difference between the exercise price of the stock warrants and the fair value of the Company’s common stock for those stock warrants that had exercise prices lower than the fair value of the Company’s common stock. The aggregate intrinsic value of outstanding warrants was approximately $67,000 at September 30, 2023.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2023
Stock Based Compensation [Abstract]
Stock Based Compensation	Note L — Stock Based Compensation The Company had a stock option plan, the 2013 Plan, which is administered by our Compensation Committee. Under the 2013 Plan, stock options to purchase a total of 4,500,000 shares of common stock could be granted to eligible employees, officers, directors and consultants of the Company. In 2020, the Company amended its 2013 Stock Option Plan (the “2013 Plan”) to increase the number of authorized shares available under the 2013 Plan from 1,800,000 to 4,500,000. On November 12, 2021, the Company adopted the 2021 Stock Incentive Plan (the “2021 Plan”) authorizing the granting of equity awards for the issuance of up to 3,000,000 shares of common stock. Prior to the adoption of the 2021 Plan, there were 2,677,500 shares available under the 2013 Plan. However, upon adoption of the 2021 Plan, no more shares would be issued under the 2013 Plan. Starting on January 1, 2022, the shares authorized under the 2021 Plan shall have an annual increase of the lessor of (a) 3.5% of the aggregate number of shares of Common Stock outstanding on the final day of the preceding calendar year, or (b) such smaller amount as determined by the Board. On January 1, 2023, an additional 238,700 shares were authorized under the 2021 Plan. The following table summarizes information about common stock options at September 30, 2023 and 2022: Number of Shares Weighted Outstanding at January 1, 2022 911,250 $ 8.57 Issued - Exercised - Forfeited - Outstanding March 31, 2022 911,250 8.57 Issued - Exercised - Forfeited - Outstanding June 30, 2022 911,250 8.57 Issued - Exercised - Forfeited (60,000 ) 11.50 Outstanding September 30, 2022 851,250 $ 8.36 Outstanding January 1, 2023 1,044,250 $ 8.48 Issued - Exercised - Forfeited - Outstanding March 31, 2023 1,044,250 8.48 Issued - Exercised - Forfeited - Outstanding June 30, 2023 1,044,250 8.48 Issued 50,000 6.43 Exercised (12,500 ) 2.00 Forfeited - Outstanding September 30, 2023 1,081,750 $ 8.46 Exercisable September 30, 2023 801,750 $ 8.10 The aggregate intrinsic value of outstanding options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The aggregate intrinsic value of options outstanding was approximately $85,000 at September 30, 2023. Employee option vesting is based on the employee’s continued service with the Company. The 2013 Plan and the 2021 Plan provide an immediate vesting of outstanding options in the event of a change of control, such as an acquisition, notwithstanding any other provision of the 2013 Plan or 2021 Plan. The following table summarizes the assumptions used to estimate the fair value of stock options issued on July 19, 2023: Stock price $ 6.43 Exercise price $ 6.43 Expected volatility 99.74 % Risk free interest rates 3.87 % Expected term 3 years At September 30, 2023, total unrecognized compensation cost related to options was approximately $1,466,000 and is expected to be recognized over the remaining weighted average service period of 1.6 years. The Company recorded stock-based compensation related to stock options in its condensed Statements of Operations as follows (approximately): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Research and Development $ 119,000 $ (21,000 ) $ 448,000 $ 286,000 General and Administrative 161,000 58,000 313,000 144,000 Total $ 280,000 $ 37,000 $ 761,000 $ 430,000 All options expire ten years from date of grant. Options outstanding begin to expire in August 2024. Options that were granted to employees and consultants have vesting periods that vary by award to recipient and range from immediate vesting to a period of up to 4 years.

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	Note M — Leases In January 2017, the Company entered into a lease for 2,534 square feet of office space in Westport, Connecticut, the “Westport Lease”). The lease commenced in May 2017. The initial lease term was two years. In November 2018, the Company exercised the option to extend the lease for an additional three years. In July 2020, the Company amended the Westport Lease to increase office space by an additional 1,653 square feet in the same building. The amended lease that includes the space included in the original lease had monthly rent as follows: Year 1 (October 2020 through September 2021) $15,502 per month ($44.43 per square foot) Year 2 (October 2021 through September 2022) $15,851 per month ($45.43 per square foot) Year 3 (October 2022 through September 2023) $16,200 per month ($46.43 per square foot) The Company had an option to extend this amended lease for an additional 3 years at the following amounts: Year 4: (October 2023 through September 2024) $16,338 per month ($46.83 per square foot) Year 5: (October 2024 through September 2025) $16,476 per month ($47.22 per square foot) Year 6: (October 2025 through September 2026) $16,825 per month ($48.22 per square foot) The Company had until March 31, 2023 to exercise this option to extend. On February 27, 2023, the Company informed the landlord that it will not exercise its option to extend the amended lease. On March 27, 2023, the Company modified the lease to reduce the office space as of April 30, 2023 and to further reduce the office space as of May 31, 2023. These two modifications reduced the operating lease asset and liability. The amended lease was set to expire on September 30, 2023. On April 17, 2023 another modification was made to the lease that terminated the lease as of June 30, 2023. The Company also paid a pro-rata share of operating expenses and real estate taxes. For the Westport Lease, the following variables were used to determine the right-of-use asset and the operating lease liabilities as of commencement date: Weighted average remaining lease term 1.00 years and Weighted average operating lease discount rate 3.92%. On July 7, 2023 the Company signed a 5.5 year lease for 2,686 square feet of office space in Shelton, Connecticut, (the “Shelton Lease”.) The initial monthly base rent payments are zero for the first six months, $2,910 for each of the next six months, and gradually increase to $3,275 per month for the last twelve months. The lease commencement date was September 1, 2023. The Company also pays a pro-rata share of common area maintenance, real estate taxes, and insurances which are treated as non-lease components and recorded as variable facilities costs on a monthly basis. The Company has a one-time option to cancel the Shelton Lease after 36 months if it provides written notice before the end of month 30. An additional $46,679 would be due at the end of month 36 if the Company exercises this option. This option is not reasonably certain to occur. The Shelton Lease uses a discount rate of 6.39% and a weighted average remaining term of 5 years 5 months The following table summarizes the balance sheet classification of the operating lease asset and related lease liabilities at September 30, 2023 for the Shelton Lease and at December 31, 2022 for the Westport Lease: September 30, December 31, Operating lease right-of-use assets $ 152,605 $ 139,089 Current portion of operating lease liabilities $ 10,556 $ 143,221 Long-term operating lease liabilities 144,891 - $ 155,447 $ 143,221

Other Uncertainties

Other Uncertainties	9 Months Ended
	Sep. 30, 2023
Other Uncertainties [Abstract]
Other Uncertainties	Note N — Other Uncertainties The Company holds one of its patents in Russia. The payment for this patent is paid until September 15, 2024. If subsequent payments to Russia are restricted, the Company may lose this patent in Russia. The Company has no other significant business activities in Belarus, Russia or the Ukraine. The Company also holds a patent in Israel which is currently involved in military action.

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2023
Related Parties [Abstract]
Related Parties	Note O — Related Parties The liabilities section of the September 30, 2023 and December 31, 2022 balance sheet shows a $36,000 deposit related to a Provider Service Agreement (“PSA”) with a minority stockholder. This account is entitled “Related party deposit” on the balance sheet. This deposit will be returned to the minority stockholder at the end of the PSA once all charges have been settled. At September 30, 2023 and December 31, 2022, the Company had a receivable of approximately none In February 2022, a minority stockholder became a consultant to the Company. Services provided include acting as the Company’s Chief Medical Officer. The Company has accrued approximately none Sublease income from the related party was approximately $23,000 and $50,600 for the nine months ended September 30, 2023 and 2022 and none

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax [Abstract]
Income Taxes	Note P — Income Taxes The Company recorded Federal research and development credits, of approximately $18,300 and $47,700 for the nine months ended September 30, 2023 and 2022, respectively. These amounts are included in Other Income in the Statements of Operations. Other current assets include a tax credit that is the Federal refundable research and development tax credit. At September 30, 2023, the Company generated Connecticut and Federal net operating loss carryforwards of approximately $30.3 million. For the Federal net operating loss carryforwards, approximately $7.0 million expire at various dates beginning in 2033. Under the Tax Cuts and Job Act passed on December 22, 2017, corporate net operating losses generated beginning in 2018 cannot be carried back but are carried forward indefinitely. The Internal Revenue Code (the “IRC”) contains limitations on the use of net operating loss carryforwards after the occurrence of substantial ownership changes as defined by IRC Section 382. Utilization of such operating loss carryforwards may be limited if such capital raises are determined to be a change in ownership under IRC Section 382. At September 30, 2023, aside from the Federal research and development tax credits used to offset Social Security taxes, the Company had Federal General Business Credit carryforwards of approximately $439,400 which are available to offset future taxable income expiring at various times beginning in 2033. At September 30, 2023, the Company has Connecticut research and development tax credit carryforwards of approximately $196,600 which are available to offset future Connecticut taxable income.

Retirement Plan _ Defined Contr

Retirement Plan – Defined Contribution	9 Months Ended
	Sep. 30, 2023
Retirement Plan – Defined Contribution [Abstract]
Retirement Plan – Defined Contribution	Note Q — Retirement Plan – Defined Contribution The Company maintains a defined contribution plan for all employees age 21 and older who have completed one month of service. This 401K plan began for payrolls after July 1, 2017. The Company makes a matching contribution equal to 100% of an employee’s contribution, up to 3% of an employee’s eligible earnings. The Company match is vested after one year of service. Retirement expense for this plan was approximately $14,700 and $29,300 for the nine months ended September 30, 2023 and 2022, respectively and approximately $4,800 and $6,000 for the three months ended September 30, 2023 and 2022, respectively.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2023
Summary of Significant Accounting Policies and Accounts [Abstact]
Basis of presentation	[1] Basis of presentation: The accompanying condensed financial statements include the accounts of Intensity Therapeutics, Inc. These condensed financial statements have been prepared in accordance with the instructions to Form 10-Q and therefore do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the United States of America (“GAAP”); however, such information reflects all adjustments consisting solely of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods. The condensed financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s prospectus, dated June 29, 2023 and filed with the Securities and Exchange Commission on June 30, 2023.
Use of estimates	[2] Use of estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Certain accounting principles require subjective and complex judgments to be used in the preparation of financial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used. The Company utilizes significant estimates and assumptions in valuing its stock-based awards. An additional significant estimate is that these financial statements are based on the assumption of the Company continuing as a going concern. See Note B with regard to the Company’s ability to continue as a going concern.
Concentration of credit risk	[3] Concentration of credit risk: The Company’s financial instruments that are exposed to concentrations of credit risk consist entirely of cash and investments in U.S. Treasury bills. These financial instruments are held at two U.S. financial institutions. The cash accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. During the nine months ended September 30, 2023 and 2022, the Company’s cash balances exceeded the FDIC insurance limit. The investments in U.S. Treasury bills are not FDIC insured but are backed by the U.S. government. U.S. Treasury bills are subject to market risk if they are sold prior to maturity. The Company has not experienced any losses in such accounts. Although the Company believes that the financial institutions with whom the Company does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so beyond amounts guaranteed by the FDIC.
Cash and cash equivalents	[4] Cash and cash equivalents: The Company considers all liquid investments with an original maturity of three months or less to be cash equivalents.
Marketable debt securities	[5] Marketable debt securities: Investments in U.S. Treasury bills purchased with an original maturity over three months are classified separately from cash and cash equivalents in current assets. Investments in U.S. Treasury bills are classified as available for sale. Under the classification of available for sale, securities are reported at fair value. Unrealized gains or losses would be included in accumulated other comprehensive income within the equity section of the Balance Sheet. At September 30, 2023, there were no unrealized gains or losses and all accrued interest was recognized as Interest income in the Statement of Operations.
Fair value measurement	[6] Fair value measurement: The Company reports its investments at fair value. Fair value is an estimate of the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (i.e., the exit price at the measurement date). Fair value measurements are not adjusted for transaction costs. A fair value hierarchy provides for prioritizing inputs to valuation techniques used to measure fair value into three levels: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company. Level 3 Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability. An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 or Level 2 assets or liabilities. At September 30, 2023, the Company has a total of approximately $9.0 million invested in U.S. Treasury Bills: none is included in cash and cash equivalents and $9.0 million is included in marketable debt securities. U.S. Treasury bills are valued at market price. U.S. Treasury Bills are categorized in Level 1 of their fair value hierarchy. At December 31, 2022, there were no investments in U.S. Treasury Bills. The Company’s financial instruments, including cash equivalents and current liabilities are carried at cost, which approximates fair value due to the short-term nature of these instruments.
Stock-based compensation	[7] Stock-based compensation: The Company accounts for stock-based compensation to employees and non-employees, which consists of stock option grants, through the Statements of Operations based on their fair values at the date of grant. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. Forfeitures are recognized as they occur.
Research and development and patent costs	[8] Research and development and patent costs: Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred, due to the uncertainty with respect to future cash flows resulting from the patents and are included as part of general and administrative expenses in the Company’s Statements of Operations.
Income taxes	[9] Income taxes: The Company accounts for income taxes through the use of the asset-and-liability method whereby deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company utilizes a valuation allowance to reduce deferred tax assets to their estimated realizable value. The Company accounts for uncertain tax positions. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At September 30, 2023, the Company does not have any significant uncertain tax positions. There are no estimated interest costs and penalties provided for in the Company’s financial statements for the nine months ended September 30, 2023. If at any time the Company should record interest and penalties in connection with income taxes, the interest and penalties will be expensed within the income tax line. The Company’s income tax returns are subject to Federal, state and local income tax examination by the authorities for the last three tax years.
Leases	[10] Leases: The Company determines if an arrangement contains a lease at contract inception. With the exception of short-term leases (leases with terms less than 12 months), all leases with contractual fixed costs are recorded on the balance sheet on the commencement date as a right-of-use (ROU) asset and a lease liability. Lease liabilities to be paid over the next twelve months are classified as current lease liability and all other lease obligations are classified as long-term lease liability. Lease liabilities are initially measured at the present value of the future minimum lease payments and subsequently increased to reflect the interest accrued and reduced by the lease payments made. The Company’s building leases require a pro-rata share of operating expenses and real estate taxes, which are variable in nature and excluded from the measurement of lease liabilities. ROU assets are initially measured at the present value of the future minimum lease payments adjusted for any prior lease pre-payments, lease incentives and initial direct costs. Certain leases contain escalation, renewal and/or termination options that are factored into the ROU asset as appropriate. Operating leases result in a straight-line rent expense over the expected lease term. The Company uses its estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of future lease payments, if the rate implicit in the lease is not readily determinable. Consideration is given to publicly available data for instruments with similar characteristics when calculating incremental borrowing rates. This incremental borrowing rate estimate is based on a synthetic credit rating derived from the market capitalization of similar companies, the treasury yield curve, and corporate yield spreads.
Basic and dilutive loss per share	[11] Basic and dilutive loss per share: Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Dilutive net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options, and stock warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per share does not include the conversion of securities that would have an anti-dilutive effect. Potential shares of common stock issuable upon conversion of preferred stock, exercise of stock options, and exercise of warrants that are excluded from the computation of diluted weighted average shares outstanding listed in the table below because they are anti-dilutive. The basic and diluted computation of net loss per share for the Company are the same because the effects of the Company’s convertible securities would be anti-dilutive. All common and preferred stock participate equally in dividends and the distribution of earnings if and when declared by the Board of Directors, on the Company’s common stock for the three and nine months ended September 30, 2022. For purposes of computing earnings per share, all series of preferred stock are considered participating securities. Therefore, the Company must calculate basic and diluted earnings per share using the two-class method. Under the two-class method, net income for the period is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed earnings. As the preferred stockholders have no obligation to fund losses no portion of net loss was allocated to the participating securities for the three months or nine months ended September 30, 2022. There were no preferred shares outstanding at September 30, 2023. At September 30, 2023 and 2022, the following shares of common stock underlying preferred stock, options, and warrants were excluded from the computation of diluted weighted average shares outstanding. In accordance with the Reverse Stock Split on April 27, 2023 (see Note A), the number of shares of common stock underlying the preferred stock, options and warrants are now half, and the below information gives effect to this Reverse Stock Split: September 30, September 30, 2023 2022 Preferred stock Series A outstanding - 2,499,999 Preferred stock Series B outstanding - 724,552 Preferred stock Series C outstanding - 900,300 Options outstanding 1,081,750 851,250 Warrants outstanding 689,200 323,250 1,770,950 5,299,351 As of September 30, 2022 the shares that would be issued from the convertible notes outstanding are also excluded from diluted weighted average shares outstanding, since the conversion rate is dependent upon qualified liquidity events. All convertible notes were converted into shares of common stock on June 29, 2023.
Stock issuance costs	[12] Stock issuance costs: The Company incurred costs related to the sale of its common stock in its IPO and the subsequent sale of common stock in the overallotment. These costs included underwriter commissions and fees, legal fees, accounting fees, and printing costs. These costs were recorded as a deduction to Additional Paid in Capital.
Recently issued pronouncements	[13] Recently issued pronouncements: The Company does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material impact on its financial statements.
Reclassifications	[14] Reclassifications: Certain prior year amounts have been reclassified to conform to current year presentation.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Accounts (Tables)	9 Months Ended
	Sep. 30, 2023
Summary of Significant Accounting Policies and Accounts [Abstact]
Schedule of Common Shares Underlying Preferred Stock, Options, and Warrants Were Excluded From Computation of Diluted Weighted Average Shares Outstanding	the number of shares of common stock underlying the preferred stock, options and warrants are now half, and the below information gives effect to this Reverse Stock Split: September 30, September 30, 2023 2022 Preferred stock Series A outstanding - 2,499,999 Preferred stock Series B outstanding - 724,552 Preferred stock Series C outstanding - 900,300 Options outstanding 1,081,750 851,250 Warrants outstanding 689,200 323,250 1,770,950 5,299,351

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	9 Months Ended
	Sep. 30, 2023
Prepaid Expenses [Abstract]
Schedule of Prepaid Expenses	Prepaid expenses at September 30, 2023 and December 31, 2022 include: September 30, December 31, Prepaid insurance $ 917,807 $ 29,359 Prepaid rent - 16,200 Prepaid other 53,432 17,365 $ 971,239 $ 62,924

Other Current Assets (Tables)

Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Other Current Assets [Abstract]
Schedule of Other Current Assets	Other current assets at September 30, 2023 and December 31, 2022 include: September 30, December 31, Tax credit receivable $ 8,785 $ 15,903 Receivable with related party - 46,401 State income tax receivable 5,581 13,231 $ 14,366 $ 75,535

Other Assets (Tables)

Other Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Other Assets [Abstract]
Schedule of Other Assets	Other assets at September 30, 2023 and December 31, 2022 include: September 30, December 31, Deposit with vendor $ - $ 150,000 Deposits with landlords 28,438 17,738 $ 28,438 $ 167,738

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2023
Accrued Expenses [Abstract]
Schedule of Accrued Expenses	Accrued expenses at September 30, 2023 and December 31, 2022 include: September 30, December 31, Accrued vacation, wages, and related payroll taxes $ - $ 328,527 Patient costs incurred but not yet invoiced 340,639 1,392,604 Accrued other 14,367 2,269 $ 355,006 $ 1,723,400

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2023
Convertible Notes [Abstract]
Schedule of Convertible Note	The balance at December 31, 2022 consists of: Principal Accrued Total Convertible note dated September 20, 2021 $ 2,000,000 $ 76,767 $ 2,076,767 Convertible notes dated November 21, 2022 750,000 8,219 758,219 Convertible note dated November 29, 2022 1,500,000 13,562 1,513,562 $ 4,250,000 $ 98,548 $ 4,348,548

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2023
Common Stock Warrants [Abstract]
Schedule of Information about Common Stock Warrants	The following table summarizes information about common stock warrants at September 30, 2023 and 2022: Number of Shares Weighted Outstanding January 1, 2022 323,250 $ 6.01 Issued - - Exercised - - Forfeited - - Outstanding March 31, 2022 323,250 6.01 Issued - Exercised - Forfeited - Outstanding June 30, 2022 323,250 6.01 Issued - Exercised - Forfeited - Outstanding September 30, 2022 323,250 $ 6.01 Outstanding January 1, 2023 357,750 $ 6.00 Issued 30,000 12.50 Exercised - Forfeited - Outstanding March 31, 2023 387,750 6.51 Issued 273,000 6.00 Exercised - Forfeited - Outstanding June 30, 2023 660,750 6.30 Issued 40,950 6.00 Exercised (12,500 ) 2.00 Forfeited - Outstanding September 30, 2023 689,200 $ 6.36 Exercisable September 30, 2023 659,450 $ 6.21
Schedule of Assumptions used to Estimate Fair Value of Stock Warrants	The following table summarizes the assumptions used to estimate the fair value of 30,000 stock warrants granted on January 1, 2023 at the date of grant: Stock price $ 4.50 Exercise price $ 6.25 Expected volatility 103.85 % Risk free interest rates 3.59 % Term 3 years Stock price $ 5.00 Exercise price $ 6.00 Expected volatility 101.46 % Risk free interest rates 3.97 % Term 5 years
Schedule of Recognized Stock-Based Compensation Expense Related to Warrants	The Company recognized stock-based compensation expense related to warrants in its condensed Statements of Operations as follows (approximately): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Research and Development $ 67,000 $ 4,000 $ 203,000 $ 11,000 General and Administrative 4,000 - 11,000 100,000 Total $ 71,000 $ 4,000 $ 214,000 $ 111,000

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Stock Based Compensation [Abstract]
Schedule of Information about Common Stock Options	The following table summarizes information about common stock options Number of Shares Weighted Outstanding at January 1, 2022 911,250 $ 8.57 Issued - Exercised - Forfeited - Outstanding March 31, 2022 911,250 8.57 Issued - Exercised - Forfeited - Outstanding June 30, 2022 911,250 8.57 Issued - Exercised - Forfeited (60,000 ) 11.50 Outstanding September 30, 2022 851,250 $ 8.36 Outstanding January 1, 2023 1,044,250 $ 8.48 Issued - Exercised - Forfeited - Outstanding March 31, 2023 1,044,250 8.48 Issued - Exercised - Forfeited - Outstanding June 30, 2023 1,044,250 8.48 Issued 50,000 6.43 Exercised (12,500 ) 2.00 Forfeited - Outstanding September 30, 2023 1,081,750 $ 8.46 Exercisable September 30, 2023 801,750 $ 8.10
Schedule of Fair Value of Stock Options	The following table summarizes the assumptions used to estimate the fair value of stock options issued on July 19, 2023: Stock price $ 6.43 Exercise price $ 6.43 Expected volatility 99.74 % Risk free interest rates 3.87 % Expected term 3 years
Schedule of Stock-based Compensation Related to Stock Options	The Company recorded stock-based compensation related to stock options in its condensed Statements of Operations as follows (approximately): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Research and Development $ 119,000 $ (21,000 ) $ 448,000 $ 286,000 General and Administrative 161,000 58,000 313,000 144,000 Total $ 280,000 $ 37,000 $ 761,000 $ 430,000

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of Original Lease Liabilities	In July 2020, the Company amended the Westport Lease to increase office space by an additional 1,653 square feet in the same building. The amended lease that includes the space included in the original lease had monthly rent as follows: Year 1 (October 2020 through September 2021) $15,502 per month ($44.43 per square foot) Year 2 (October 2021 through September 2022) $15,851 per month ($45.43 per square foot) Year 3 (October 2022 through September 2023) $16,200 per month ($46.43 per square foot) Year 4: (October 2023 through September 2024) $16,338 per month ($46.83 per square foot) Year 5: (October 2024 through September 2025) $16,476 per month ($47.22 per square foot) Year 6: (October 2025 through September 2026) $16,825 per month ($48.22 per square foot)
Schedule of Operating Lease Asset and Related Lease Liabilities	The following table summarizes the balance sheet classification of the operating lease asset and related lease liabilities at September 30, 2023 for the Shelton Lease and at December 31, 2022 for the Westport Lease: September 30, December 31, Operating lease right-of-use assets $ 152,605 $ 139,089 Current portion of operating lease liabilities $ 10,556 $ 143,221 Long-term operating lease liabilities 144,891 - $ 155,447 $ 143,221

Nature of Business (Details)

Nature of Business (Details) - USD ($)			1 Months Ended	9 Months Ended
	Jul. 07, 2023	Jul. 05, 2023	Apr. 27, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Nature of Business [Line Items]
Common stock shares issued (in Shares)				13,709,377		3,410,103
Net cash proceeds		$ 19,500,000		$ 19,500,000
Initial public offering				$ 264,000
Reverse stock split			On April 27, 2023, the Company effected a two-for-one reverse stock split (the “Reverse Stock Split”). All owners of record as of April 27, 2023 received one issued and outstanding share of the Company’s common stock in exchange for two outstanding shares of the Company’s common stock. All fractional shares created by the two-for-one exchange were paid in cash. The conversion price of Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock were adjusted to reflect the Reverse Stock Split by doubling the original conversion price. The Reverse Stock Split has no impact on the par value per share of the Company’s common stock, Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock, all of which remain at $.0001. All holders of options and warrants had the exercise price doubled and the number of shares issuable upon exercise reduced by half. All current and prior period amounts related to shares, share prices and loss per share, presented in the Company’s financial statements and the accompanying notes have been restated for the Reverse Stock Split. All preferred stock and convertible notes that were issued during the pre-IPO period were converted into common stock.
IPO [Member]
Nature of Business [Line Items]
Common stock shares issued (in Shares)		3,900,000
Net cash proceeds		$ 17,765,000
Over-Allotment Option [Member]
Nature of Business [Line Items]
Common stock shares issued (in Shares)	585,000
Net cash proceeds	$ 2,691,000
Series A Preferred Stock [Member]
Nature of Business [Line Items]
Convertible preferred stock, par value (in Dollars per share)				$ 0.0001		$ 0.0001
Series B Preferred Stock [Member]
Nature of Business [Line Items]
Preferred stock par value (in Dollars per share)				0.0001		0.0001
Series C Preferred Stock [Member]
Nature of Business [Line Items]
Preferred stock par value (in Dollars per share)				$ 0.0001		$ 0.0001

Liquidity and Plan of Operati_2

Liquidity and Plan of Operation (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Liquidity and Plan of Operation [Line Items]
Accumulated deficit	$ 47.3
Net loss	7.4
Cash and cash equivalents	6.7
Total investment marketable debt securities	9
Total investment marketable debt securities	9
Cash Equivalents [Member]
Liquidity and Plan of Operation [Line Items]
Total investment marketable debt securities	$ 15.7

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Accounts (Details)	Sep. 30, 2023 USD ($)
Summary of Significant Accounting Policies and Accounts [Line Items]
Marketable securities	$ 9,000,000
Cash and cash equivalents	0
Debt Securities [Member]
Summary of Significant Accounting Policies and Accounts [Line Items]
Marketable securities	$ 9,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Accounts (Details) - Schedule of Common Shares Underlying Preferred Stock, Options, and Warrants Were Excluded From Computation of Diluted Weighted Average Shares Outstanding - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,770,950	5,299,351
Options outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,081,750	851,250
Warrants outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	689,200	323,250
Preferred stock Series A outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		2,499,999
Preferred stock Series B outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		724,552
Preferred stock Series C outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		900,300

Marketable Debt Securities (Det

Marketable Debt Securities (Details)	Sep. 30, 2023 USD ($)
Marketable Debt Securities [Abstract]
Maturity value	$ 9,030,000
U.S.Treasury bills purchased	8,844,400
Market value	$ 8,955,300

Prepaid Expenses (Details) - Sc

Prepaid Expenses (Details) - Schedule of Prepaid Expenses - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Schedule of Prepaid Expenses [Abstract]
Prepaid insurance	$ 917,807	$ 29,359
Prepaid rent		16,200
Prepaid other	53,432	17,365
Prepaid expenses	$ 971,239	$ 62,924

Other Current Assets (Details)

Other Current Assets (Details) - Schedule of Other Current Assets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Schedule Of Other Current Assets Abstract
Tax credit receivable	$ 8,785	$ 15,903
Receivable with related party		46,401
State income tax receivable	5,581	13,231
Total other current assets	$ 14,366	$ 75,535

Other Assets (Details) - Schedu

Other Assets (Details) - Schedule of Other Assets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Schedule of Other Current Assets [Abstract]
Deposit with vendor		$ 150,000
Deposits with landlords	28,438	17,738
Total other assets	$ 28,438	$ 167,738

Accrued Expenses (Details) - Sc

Accrued Expenses (Details) - Schedule of Accrued Expenses - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Schedule of Accrued Expenses [Abstract]
Accrued vacation, wages, and related payroll taxes		$ 328,527
Patient costs incurred but not yet invoiced	340,639	1,392,604
Accrued other	14,367	2,269
Total accrued expenses	$ 355,006	$ 1,723,400

Convertible Notes (Details)

Convertible Notes (Details) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

May 11, 2023

Apr. 01, 2023

Mar. 30, 2023

Nov. 29, 2022

Nov. 21, 2022

Sep. 20, 2021

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

Mar. 16, 2023

Dec. 31, 2022

Convertible Notes (Details) [Line Items]

Loss on debt conversion

$ (2,261,581)

Converted shares (in Shares)

1,399,716

Unamortized balance

$ 117,700

2021 Convertible Note [Member]

Convertible Notes (Details) [Line Items]

Aggregate principal

$ 2,000,000

Due date

Oct. 01, 2025

Debt terms

The outstanding principal balance together with the unpaid and accrued interest of the note would be automatically converted upon the earlier of (i) an IPO in excess of $7,000,000 gross proceeds, (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non-IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of October 1, 2025. If an IPO, sale event or Non-IPO financing occurred between September 20, 2021 through September 19, 2022 a conversion price discount of 25% would be assessed, if between September 20, 2022 through March 19, 2023 a conversion price discount of 30% would be assessed, if between March 20, 2023 through October 1, 2025 a conversion price discount of 35% would be assessed.

Debt conversion price (in Dollars per share)

$ 11.5

Interest rate

6%

3%

Amount of judgements in excess defaults under indebtedness

$ 500,000

November 21, 2022 Convertible Notes One [Member]

Convertible Notes (Details) [Line Items]

Aggregate principal

$ 250,000

November 21, 2022 Convertible Notes Two [Member]

Convertible Notes (Details) [Line Items]

Aggregate principal

$ 500,000

November 21, 2022 Convertible Notes [Member]

Convertible Notes (Details) [Line Items]

Debt terms

The outstanding principal balance together with the unpaid and accrued interest of the note would be automatically converted upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds, as amended (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non-IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of November 21, 2024. If an IPO, sale event or Non-IPO financing occurred prior to November 21, 2024 a conversion price discount of 30% would be assessed.

Debt conversion price (in Dollars per share)

$ 11.5

Interest rate

10%

Amount of judgements in excess defaults under indebtedness

$ 500,000

November 29, 2022 Convertible Note [Member]

Convertible Notes (Details) [Line Items]

Aggregate principal

$ 1,500,000

Debt terms

The outstanding principal balance together with the unpaid and accrued interest of the note would be automatically converted upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds, as amended (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of October 1, 2025. If an IPO, sale event or Non-IPO financing occurred prior to October 1, 2025 a conversion price discount of 30% would be assessed.

Debt conversion price (in Dollars per share)

$ 11.5

Interest rate

10%

Amount of judgements in excess defaults under indebtedness

$ 500,000

March 16, 2023 Convertible Note [Member]

Convertible Notes (Details) [Line Items]

Aggregate principal

$ 50,000

March 30, 2023 Convertible Note [Member]

Convertible Notes (Details) [Line Items]

Aggregate principal

$ 155,000

Debt terms

The outstanding principal balances together with the unpaid and accrued interest of these notes would be automatically converted upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of March 16, 2026 for the March 16, 2023 Convertible Note and March 30, 2026 for the March 30, 2023 Convertible Note. If an IPO, sale event or Non-IPO financing occurred prior to March 16, 2026 for the March 16, 2023 Convertible Note or prior to March 30, 2026 for the March 30, 2023 Convertible Note, a conversion price discount of 30% would be assessed.

Debt conversion price (in Dollars per share)

$ 11.5

Interest rate

10%

Amount of judgements in excess defaults under indebtedness

$ 500,000

April 1, 2023 Convertible Note [Member]

Convertible Notes (Details) [Line Items]

Aggregate principal

$ 12,552

Debt terms

The outstanding principal balances together with the unpaid and accrued interest of these notes would be automatically converted upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of April 1, 2026. If an IPO, sale event or Non-IPO financing occurred prior to April 1, 2026, a conversion price discount of 30% would be assessed.

Debt conversion price (in Dollars per share)

$ 11.5

Interest rate

10%

Amount of judgements in excess defaults under indebtedness

$ 500,000

May 11, 2023 Convertible Note [Member]

Convertible Notes (Details) [Line Items]

Aggregate principal

$ 25,000

Debt terms

The outstanding principal balances together with the unpaid and accrued interest of these notes would be automatically converted upon the earlier of (i) an IPO of no less than $7,000,000 gross proceeds (ii) a sale event of all or substantially all of the company’s assets or a majority of its equity securities, (iii) Non- IPO financing by selling preferred stock in an equity offering other than an IPO or (iv) maturity date of May 11, 2026. If an IPO, sale event or Non-IPO financing occurred prior to May 11, 2026, a conversion price discount of 30% would be assessed.

Debt conversion price (in Dollars per share)

$ 11.5

Interest rate

10%

Amount of judgements in excess defaults under indebtedness

$ 500,000

June 29, 2023 Convertible Notes [Member]

Convertible Notes (Details) [Line Items]

Convertible notes of principal amount

$ 4,492,552

Convertible notes of accured interest

$ 244,447

Convertible Notes (Details) - S

Convertible Notes (Details) - Schedule of Convertible Note	Dec. 31, 2022 USD ($)
Convertible Notes (Details) - Schedule of Convertible Note [Line Items]
Principal	$ 4,250,000
Accrued Interest	98,548
Total	4,348,548
Convertible note dated September 20, 2021 [Member]
Convertible Notes (Details) - Schedule of Convertible Note [Line Items]
Principal	2,000,000
Accrued Interest	76,767
Total	2,076,767
Convertible notes dated November 21, 2022 [Member]
Convertible Notes (Details) - Schedule of Convertible Note [Line Items]
Principal	750,000
Accrued Interest	8,219
Total	758,219
Convertible note dated November 29, 2022 [Member]
Convertible Notes (Details) - Schedule of Convertible Note [Line Items]
Principal	1,500,000
Accrued Interest	13,562
Total	$ 1,513,562

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)		3 Months Ended		9 Months Ended
	Jul. 07, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 29, 2023	Nov. 23, 2021
Stockholders’ Equity (Details) [Line Items]
Loss on debt extinguishment (in Dollars)				$ (2,261,581)
IPO [Member]
Stockholders’ Equity (Details) [Line Items]
Conversion of common stock				1,399,716
Number of shares sold	585,000
Price per share (in Dollars per share)	$ 5
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Conversion of common stock				1,399,716
Common Stock [Member] | IPO [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock shares issuing						3,900,000
Minimum [Member]
Stockholders’ Equity (Details) [Line Items]
Authorized shares							50,000,000
Maximum [Member]
Stockholders’ Equity (Details) [Line Items]
Authorized shares							135,000,000
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Additional shares issued		100,189		100,189
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Additional shares issued		164,518		164,518

Common Stock Warrants (Details)

Common Stock Warrants (Details) - USD ($)		9 Months Ended
	Jan. 01, 2023	Sep. 30, 2023
Common Stock Warrants (Details) [Line Items]
Value of warrants		$ 153,000
Warrants granted underwriters sale of overallotment shares		$ 40,950
Weighted average service period		1 year 7 months 6 days
Common Stock Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Fair value of estimate stock warrants granted (in Shares)	30,000
Total unrecognized compensation cost		$ 164,000
Weighted average service period		1 year 10 months 24 days
Aggregate intrinsic value of outstanding warrants		$ 67,000
Common Stock Warrants [Member] | IPO [Member]
Common Stock Warrants (Details) [Line Items]
Value of warrants		$ 1,017,000
Warrants granted underwriters of IPO base shares (in Shares)		273,000
Common Stock Warrants [Member] | Two Holders of Convertible Notes [Member]
Common Stock Warrants (Details) [Line Items]
Fair value stock warrants granted (in Shares)	30,000
Value of warrants		$ 159,262

Common Stock Warrants (Detail_2

Common Stock Warrants (Details) - Schedule of Information about Common Stock Warrants - Common Stock Warrants [Member] - $ / shares	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023
Product Information [Line Items]
Number of Shares Underlying Warrants, Outstanding Beginning Balance	660,750	387,750	357,750	323,250	323,250	323,250	357,750
Weighted Average Exercise Price, Outstanding Beginning Balance (in Dollars per share)	$ 6.3	$ 6.51	$ 6	$ 6.01	$ 6.01	$ 6.01	$ 6
Number of Shares Underlying Warrants, Issued	40,950	273,000	30,000
Weighted Average Exercise Price, Issued (in Dollars per share)	$ 6	$ 6	$ 12.5
Number of Shares Underlying Warrants, Exercised	(12,500)
Weighted Average Exercise Price, Exercised (in Dollars per share)	$ 2
Number of Shares Underlying Warrants, Forfeited
Weighted Average Exercise Price, Forfeited (in Dollars per share)
Number of Shares Underlying Warrants, Outstanding Ending Balance	689,200	660,750	387,750	323,250	323,250	323,250	689,200
Weighted Average Exercise Price, Outstanding Ending Balance (in Dollars per share)	$ 6.36	$ 6.3	$ 6.51	$ 6.01	$ 6.01	$ 6.01	$ 6.36
Number of Shares Underlying Warrants, Exercisable	659,450						659,450
Weighted Average Exercise Price, Exercisable (in Dollars per share)	$ 6.21						$ 6.21

Common Stock Warrants (Detail_3

Common Stock Warrants (Details) - Schedule of Assumptions used to Estimate Fair Value of Stock Warrants	9 Months Ended
	Sep. 30, 2023 $ / shares
Common Stock Warrants (Details) - Schedule of Assumptions used to Estimate Fair Value of Stock Warrants [Line Items]
Stock price	$ 5
Exercise price	$ 6
Expected volatility	101.46%
Risk free interest rates	3.97%
Expected term	5 years
Common Stock Warrants [Member]
Common Stock Warrants (Details) - Schedule of Assumptions used to Estimate Fair Value of Stock Warrants [Line Items]
Stock price	$ 4.5
Exercise price	$ 6.25
Expected volatility	103.85%
Risk free interest rates	3.59%
Expected term	3 years

Common Stock Warrants (Detail_4

Common Stock Warrants (Details) - Schedule of Recognized Stock-Based Compensation Expense Related to Warrants - Common Stock Warrants [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Common Stock Warrants (Details) - Schedule of Recognized Stock-Based Compensation Expense Related to Warrants [Line Items]
Total	$ 71,000	$ 4,000	$ 214,000	$ 111,000
Research and Development Expense [Member]
Common Stock Warrants (Details) - Schedule of Recognized Stock-Based Compensation Expense Related to Warrants [Line Items]
Total	67,000	4,000	203,000	11,000
General and Administrative Expense [Member]
Common Stock Warrants (Details) - Schedule of Recognized Stock-Based Compensation Expense Related to Warrants [Line Items]
Total	$ 4,000		$ 11,000	$ 100,000

Stock Based Compensation (Detai

Stock Based Compensation (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Jan. 01, 2023
Stock Based Compensation (Details) [Line Items]
Aggregate intrinsic value of options outstanding (in Dollars)	$ 85,000
Total unrecognized compensation cost (in Dollars)	$ 1,466,000
Weighted average service period	1 year 7 months 6 days
Options expire period	10 years
Vesting period	4 years
2013 Plan [Member]
Stock Based Compensation (Details) [Line Items]
Available shares	2,677,500
2021 Plan [Member]
Stock Based Compensation (Details) [Line Items]
Issuance of common shares	3,000,000
Available shares		238,700
Percentage of aggregate number of shares of Common Stock outstanding	3.50%
Minimum [Member] | 2013 Plan [Member]
Stock Based Compensation (Details) [Line Items]
Number of authorized shares available	1,800,000
Maximum [Member] | 2013 Plan [Member]
Stock Based Compensation (Details) [Line Items]
Number of authorized shares available	4,500,000
Employees Officers Directors and Consultants [Member] | 2013 Plan [Member]
Stock Based Compensation (Details) [Line Items]
Number of authorized shares available	4,500,000

Stock Based Compensation (Det_2

Stock Based Compensation (Details) - Schedule of Information about Common Stock Options - $ / shares	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Schedule Of Information About Common Stock Options Abstract
Number of Shares Underlying Options, Outstanding at beginning			1,044,250			911,250
Weighted Average Exercise Price, Outstanding at beginning (in Dollars per share)	$ 8.48	$ 8.48	$ 8.48	$ 8.57	$ 8.57	$ 8.57
Number of Shares Underlying Options, Issued	50,000
Weighted Average Exercise Price, Issued (in Dollars per share)	$ 6.43
Number of Shares Underlying Options, Exercised	(12,500)
Weighted Average Exercise Price, Exercised (in Dollars per share)	$ 2
Number of Shares Underlying Options, Forfeited				(60,000)
Weighted Average Exercise Price, Forfeited (in Dollars per share)				$ 11.5
Number of Shares Underlying Options, Outstanding at Ending	1,081,750	1,044,250	1,044,250	851,250	911,250	911,250
Weighted Average Exercise Price, Outstanding at Ending (in Dollars per share)	$ 8.46	$ 8.48	$ 8.48	$ 8.36	$ 8.57	$ 8.57
Number of Shares Underlying Options, Exercisable	801,750
Weighted Average Exercise Price, Exercisable (in Dollars per share)	$ 8.1

Stock Based Compensation (Det_3

Stock Based Compensation (Details) - Schedule of Fair Value of Stock Options - Stock Options [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares
Stock Based Compensation (Details) - Schedule of Fair Value of Stock Options [Line Items]
Stock price	$ 6.43
Exercise price	$ 6.43
Expected volatility	99.74%
Risk free interest rates	3.87%
Expected term	3 years

Stock Based Compensation (Det_4

Stock Based Compensation (Details) - Schedule of Stock-based Compensation Related to Stock Options - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Related Party Transaction [Line Items]
Total	$ 280,000	$ 37,000	$ 761,000	$ 430,000
Research and Development Expense [Member]
Related Party Transaction [Line Items]
Total	119,000	(21,000)	448,000	286,000
General and Administrative Expense [Member]
Related Party Transaction [Line Items]
Total	$ 161,000	$ 58,000	$ 313,000	$ 144,000

Leases (Details)

Leases (Details)		9 Months Ended
	Jul. 07, 2023 USD ($) m²	Sep. 30, 2023 USD ($)	Jul. 31, 2020 m²	Nov. 30, 2018	Jan. 31, 2017 ft²
Leases (Details) [Line Items]
Office space square feet	2,686		1,653		2,534
Lease term	5 years 6 months				2 years
Extension of lease term				3 years
Weighted average remaining lease term		5 years 5 months
Weighted average operating lease discount rate percentage		6.39%
Office space lease cost		$ 46,679
Rent expense		$ 54,547
First Six Months [Member]
Leases (Details) [Line Items]
Rent payments	$ 0
Next Six Months [Member]
Leases (Details) [Line Items]
Rent payments	2,910
Last Twelve Months [Member]
Leases (Details) [Line Items]
Rent payments	$ 3,275
Westport Lease [Member]
Leases (Details) [Line Items]
Weighted average remaining lease term		1 year
Weighted average operating lease discount rate percentage		3.92%
Shelton Lease [Member]
Leases (Details) [Line Items]
Rent expense		$ 2,842

Leases (Details) - Schedule of

Leases (Details) - Schedule of Original Lease Liabilities	9 Months Ended
	Sep. 30, 2023
Year 1 (October 2020 through September 2021) [Member]
Leases (Details) - Schedule of Original Lease Liabilities [Line Items]
Operating lease per month	$15,502 per month
Operating lease per square foot	($44.43 per square foot)
Year 2 (October 2021 through September 2022) [Member]
Leases (Details) - Schedule of Original Lease Liabilities [Line Items]
Operating lease per month	$15,851 per month
Operating lease per square foot	($45.43 per square foot)
Year 3 (October 2022 through September 2023) [Member]
Leases (Details) - Schedule of Original Lease Liabilities [Line Items]
Operating lease per month	$16,200 per month
Operating lease per square foot	($46.43 per square foot)
Year 4: (October 2023 through September 2024) [Member]
Leases (Details) - Schedule of Original Lease Liabilities [Line Items]
Operating lease per month	$16,338 per month
Operating lease per square foot	($46.83 per square foot)
Year 5: (October 2024 through September 2025) [Member]
Leases (Details) - Schedule of Original Lease Liabilities [Line Items]
Operating lease per month	$16,476 per month
Operating lease per square foot	($47.22 per square foot)
Year 6: (October 2025 through September 2026) [Member]
Leases (Details) - Schedule of Original Lease Liabilities [Line Items]
Operating lease per month	$16,825 per month
Operating lease per square foot	($48.22 per square foot)

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Operating Lease Asset and Related Lease Liabilities - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Schedule Of Operating Lease Asset And Related Lease Liabilities Abstract
Operating lease right-of-use assets	$ 152,605	$ 139,089
Current portion of operating lease liabilities	10,556	143,221
Long-term operating lease liabilities	144,891
Total	$ 155,447	$ 143,221

Related Parties (Details)

Related Parties (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Related Parties [Abstract]
Deposit related	$ 36,000		$ 36,000		$ 36,000
Related to agreement					46,400
Agreement accrued					$ 95,900
Expenses related to consulting agreement	2,200	$ 15,000	6,200	$ 80,900
Sublease income from the related party		$ 16,900	$ 23,000	$ 50,600

Income Taxes (Details)

Income Taxes (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Income Taxes (Details) [Line Items]
Research and development credits	$ 18,300	$ 47,700
Net operating loss carryforwards	30,300,000
Domestic Tax Authority [Member]
Income Taxes (Details) [Line Items]
Net operating loss carryforwards	7,000,000
Research and development tax credit carryforwards	439,400
State and Local Jurisdiction [Member]
Income Taxes (Details) [Line Items]
Research and development tax credit carryforwards	$ 196,600

Retirement Plan _ Defined Con_2

Retirement Plan – Defined Contribution (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Retirement Plan – Defined Contribution [Abstract]
Employee’s contribution			100%
Employee’s eligible earnings			3%
Retirement expense	$ 4,800	$ 6,000	$ 14,700	$ 29,300